| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.06 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.075 | 0.06 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.081 | 0.06 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | 0.54 | 0.06 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | StemRegenin 1 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.079 | 0.06 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.078 | 0.06 |